Trial site
Sarah Cannon Research Institute at HealthONE
- 23running trials
- 16closed trials
The trials here
What the 39 trials at this site are about, from their registry records.
- Conditions
- Lung cancer30 trials
- Colorectal cancer15 trials
- Ovarian cancer15 trials
- Pancreatic cancer14 trials
- Head and neck cancer12 trials
- Triple-negative breast cancer11 trials
- Kidney cancer10 trials
- Gastric and oesophageal cancer8 trials
- Melanoma8 trials
- Prostate cancer8 trials
- Bladder cancer7 trials
- Sarcoma6 trials
- and 12 more
- Phase
- Phase 125 trials
- Phase 1/213 trials
- Phase 21 trial
- Status
- Recruiting14 trials
- Terminated10 trials
- Active, not recruiting9 trials
- Completed5 trials
- Withdrawn1 trial
- Lead sponsor
- Eli Lilly and Company4 trials
- Pfizer3 trials
- BicycleTx Limited2 trials
- IDEAYA Biosciences2 trials
- NiKang Therapeutics, Inc.2 trials
- and 24 more
Running trials
Recruiting
Recruiting
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Recruiting
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Recruiting
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Recruiting
A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
Recruiting
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Recruiting
Active, not recruiting
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Active, not recruiting
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Recruiting
Recruiting
Active, not recruiting
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
Recruiting
Active, not recruiting
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Recruiting
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Recruiting
Active, not recruiting
Recruiting
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Recruiting
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Active, not recruiting
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
Active, not recruiting
Active, not recruiting
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
Active, not recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Lung cancer10 recruiting
- Ovarian cancer5 recruiting
- Pancreatic cancer5 recruiting
- Triple-negative breast cancer5 recruiting
- Colorectal cancer4 recruiting
- Head and neck cancer4 recruiting
- Gastric and oesophageal cancer3 recruiting
- Kidney cancer3 recruiting
- Prostate cancer3 recruiting
- Bladder cancer2 recruiting
- Endometrial cancer2 recruiting
- Melanoma2 recruiting
- Neuroendocrine tumours2 recruiting
- Brain metastases1 recruiting
- Cervical cancer1 recruiting
- Mesothelioma1 recruiting
- Metastatic breast cancer1 recruiting
Closed trials
Terminated
Terminated
A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer
Terminated
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
Terminated
Withdrawn
Terminated
Study of RO7515629 in Participants With HLA-G Positive Solid Tumors
Completed
Terminated
Completed
Completed
A Study of PRT2527 in Participants With Advanced Solid Tumors
Terminated
A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma
Terminated
Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma
Terminated
Terminated
Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
Completed
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Completed
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
Site data: ClinicalTrials.govUpdated 12 Nov 2026